EVALUATION OF ANTIBIOTICS IN COVID-19 INTENSIVELY HOSPITALIZED PATIENTS WITH PNEUMONIA AT THE H.S SAMSOERI MERTOJOSO HOSPITAL
Article metrics
OJS usage and citation sourcesViews and downloads are recorded by OJS; statistics processing may be delayed. A dash means the source count is unavailable. Search Google Scholar
Article Sidebar
Oki Nugraha Putra, Mida Purwiningtyas, Anisatul Widad (2022). EVALUATION OF ANTIBIOTICS IN COVID-19 INTENSIVELY HOSPITALIZED PATIENTS WITH PNEUMONIA AT THE H.S SAMSOERI MERTOJOSO HOSPITAL. Journal of Pharmaceutical and Sciences, Vol. 5 No. 2 (2022): JPS Volume 5 Nomor 2 (2022). https://doi.org/10.36490/journal-jps.com.v5i2.146
Main Article Content
Abstract
COVID-19 pneumonia is one of the complications in COVID-19 patients with a high mortality rate. Patients with COVID-19 pneumonia require intensive care if respiratory failure occurs or oxygen saturation (SpO2) is below 93%. Antibiotics are one treatment modality, and their evaluation is needed to support rational use. This study examined the appropriateness of antibiotics given to patients with COVID-19 pneumonia in the intensive care unit of Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya, including the route of administration, type, dose, frequency, duration, and therapeutic outcome. This retrospective study used medical records of patients treated from January to July 2021. Fifty-eight patients met the inclusion criteria. Levofloxacin, meropenem, and cefoperazone-sulbactam were the most commonly administered antibiotics, accounting for 33%, 24%, and 19%, respectively. All antibiotics were administered intravenously by the correct route. Eight antibiotics were appropriate in type and dose; two were not appropriate in frequency. In general, treatment duration followed the guidelines. More patients died during treatment than recovered. The study concluded that antibiotics were given with the appropriate type, route, dose, and timing, and called for continued efforts by hospital health workers to support rational antibiotic use.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
): Experience from 350 patients. Infection and Drug Resistance.13: 3907–3918.
Jang SY., Seon JY., Yoon SJ., Park SY., Lee SH., Oh IH. (2021). Comorbidities and factors determining medical expenses and length of stay for admitted covid-19 patients in Korea. Risk Management and Healthcare Policy. 14: 2021–2033.
Juneja D., Savio RD., Srinivasan S., Pandit RA., Ramasubban S., Reddy PK., et al. 2020). Basic critical care for management of COVID-19 patients: Position paper of Indian society of critical care medicine, Part II. Indian Journal of Critical Care Medicine. 24 (Suppl 5): 254–262.
Karampela I & Dalamaga M. (2020). Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Archives of Medical Research. 51(7): 741–742.
Kariyawasam RM., Julien DA., Jelinski DC., Larose SL., Rennert-May E., Conly JM., et al. (2022). Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis. Antimicrobial Resistance and Infection Control. 11:45
Klutts GN., Squires A., Bowman SM., Bhavaraju A., Kalkwarf KJ. (2022). Increased Lengths of Stay, ICU, and Ventilator Days in Trauma Patients with Asymptomatic COVID-19 Infection. American Surgeon. 88(7):1522–1525.
Kumar A., Jaggi S., Singh S., Dutta K. (2021). Covid-19 pneumonia: An unusual radiological presentation. Indian Journal of Tuberculosis. 68(4):527–528.
Luque S., Benítez-Cano A., Larrañaga L., Sorlí L., Navarrete ME., Campillo N., et al. (2021). Pharmacokinetics and pharmacodynamics of meropenem by extended or continuous infusion in low body weight critically ill patients. Antibiotics.10:666.
Mansab F., Donnelly H., Kussner A., Neil J., Bhatti S., Goyal K. (2021). Oxygen and Mortality in COVID-19 Pneumonia: A Comparative Analysis of Supplemental Oxygen Policies and Health Outcomes Across 26 Countries. Frontiers in Public Health. 9:580585
Ng TM., Ong SWX., Loo AYX., Tan SH., Tay HL., Yap MY., et al. (2022). Antibiotic Therapy in the Treatment of COVID-19 Pneumonia: Who and When? Antibiotics. 11:184
Rees EM., Nightingale ES., Jafari Y., Waterlow NR., Clifford S., Carl CA., et al. (2020). COVID-19 length of hospital stay: A systematic review and data synthesis. BMC Medicine. 18:270
Rousan LA., Elobeid E., Karrar M., Khader Y. (2020). Chest x-ray findings and temporal lung changes in patients with COVID-19 pneumonia. BMC Pulmonary Medicine. 20:245
Rozaliyani A., Savitri AI., Setianingrum F., Shelly TN., Ratnasari V., Kuswindarti R., et al. (2020). Factors Associated with Death in COVID-19 Patients in Jakarta, Indonesia: An Epidemiological Study. Acta Med Indones-Indones J Intern Med. 52(3):246-254
Sieswerda E., de Boer MG., Bonten MMJ., Boersma WG., Jonkers RE., Aleva RM., et al. (2021). Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clinical Microbiology and Infection. 27:61–66.
Soemarwoto RA., Marlina N., Mustofa S., Sinaga F., Gozali A., Dwi R, Hapsari TK. (2020). Clinical Characteristics of COVID-19 Pneumonia Patients in Abdoel Moeloek Regional Public Hospital, Bandar Lampung, Indonesia. JK Unila. 4(1):1-11
Soni M., Gopalakrishnan R., Vaishya R., Prabu P. (2020). D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 14(6):2245–2249.
Surendra H., Elyazar IR., Djaafara BA., Ekawati LL., Saraswati K., Adrian V., et al. (2021). Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. The Lancet Regional Health - Western Pacific. 9:100108
Susilo A., Martin RC., Pitoyo CW., Djoko SW., Yulianti M., Sinto R., et al. (2020). Coronavirus Disease 2019: Tinjauan Pustaka. Jurnal Penyakit Dalam Indonesia. 7;1:45-67
Tetaj N., Capone A., Stazi, GV., Marini MC., Garotto G., Busso D., et al. (2022). Epidemiology of ventilator-associated pneumonia in ICU COVID-19 patients: an alarming high rate of multidrug-resistant bacteria. Journal of Anesthesia, Analgesia and Critical Care. 2: 36.
Zaragoza R., Vidal-Cortés P., Aguilar G., Borges M., Diaz E., Ferrer R., et al. (2020). Update of the treatment of nosocomial pneumonia in the ICU. Critical Care. 24:383